Evaluation of inter- and intra-variability in gut health markers in healthy adults using an optimised faecal sampling and processing method.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
19 Oct 2024
19 Oct 2024
Historique:
received:
26
07
2024
accepted:
07
10
2024
medline:
20
10
2024
pubmed:
20
10
2024
entrez:
19
10
2024
Statut:
epublish
Résumé
Despite advances in gut health research, the variability of important gut markers within individuals over time remains underexplored. We investigated the intra-individual variation of various faecal gut health markers using an optimised processing protocol aimed at reducing variability. Faecal samples from ten healthy adults over three consecutive days demonstrated marker-specific intra-individual coefficients of variation (CV%), namely: stool consistency (16.5%), water content (5.7%), pH (3.9%), total SCFAs (17.2%), total BCFAs (27.4%), total bacteria and fungi copies (40.6% and 66.7%), calprotectin and myeloperoxidase (63.8% and 106.5%), and untargeted metabolites (on average 40%). For thirteen microbiota genera, including Bifidobacterium and Akkermansia, variability exceeded 30%, whereas microbiota diversity was less variable (Phylogenetic Diversity 3.3%, Inverse Simpson 17.2%). Mill-homogenisation of frozen faeces significantly reduced the replicates CV% for total SCFAs (20.4-7.5%) and total BCFAs (15.9-7.8%), and untargeted metabolites compared to faecal hammering only, without altering mean concentrations. Our results show the potential need for repeated sampling to accurately represent specific gut health markers. We also demonstrated the effectiveness of optimised preprocessing of human stool samples in reducing overall analytical variability.
Identifiants
pubmed: 39427011
doi: 10.1038/s41598-024-75477-z
pii: 10.1038/s41598-024-75477-z
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24580Subventions
Organisme : Horizon 2020 Framework Programme of the European Union (ITN SmartAge)
ID : H2020-MSCA-ITN-2019-859890
Organisme : Horizon 2020 Framework Programme of the European Union (ITN SmartAge)
ID : H2020-MSCA-ITN-2019-859890
Organisme : The Dutch Research Council (NWO).
ID : MOCIA 17611
Informations de copyright
© 2024. The Author(s).
Références
Ahlawat, S., Asha & Sharma, K. K. Gut-organ axis: A microbial outreach and networking. Lett. Appl. Microbiol. 72(6), 636–668 (2021).
pubmed: 32472555
doi: 10.1111/lam.13333
Lama Tamang, R. et al. The diet-microbiota axis: A key regulator of intestinal permeability in human health and disease. Tissue Barriers. 2077069 (2022).
Ghosh, T. S. et al. Adjusting for age improves identification of gut microbiome alterations in multiple diseases. Elife 9(2020).
Durack, J. & Lynch, S. V. The gut microbiome: Relationships with disease and opportunities for therapy. J. Exp. Med. 216(1), 20–40 (2019).
pubmed: 30322864
pmcid: 6314516
doi: 10.1084/jem.20180448
He, Y. et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat. Med. 24(10), 1532–1535 (2018).
pubmed: 30150716
doi: 10.1038/s41591-018-0164-x
Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature. 486(7402), 222–227 (2012).
pubmed: 22699611
pmcid: 3376388
doi: 10.1038/nature11053
Asnicar, F. et al. Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. Nat. Med. 27(2), 321–332 (2021).
pubmed: 33432175
pmcid: 8353542
doi: 10.1038/s41591-020-01183-8
Campaniello, D. et al. How diet and physical activity modulate gut microbiota: Evidence, and perspectives. Nutrients 14(12). (2022).
Huang, X. et al. Dietary variety relates to gut microbiota diversity and abundance in humans. Eur. J. Nutr.(2022).
Aya, V. et al. Association between physical activity and changes in intestinal microbiota composition: A systematic review. PLoS One. 16(2), e0247039 (2021).
pubmed: 33630874
pmcid: 7906424
doi: 10.1371/journal.pone.0247039
Dziewiecka, H. et al. Physical activity induced alterations of gut microbiota in humans: A systematic review. BMC Sports Sci. Med. Rehabil. 14(1), 122 (2022).
pubmed: 35799284
pmcid: 9264679
doi: 10.1186/s13102-022-00513-2
Vich Vila, A. et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat. Commun. 11(1), 362 (2020).
pubmed: 31953381
pmcid: 6969170
doi: 10.1038/s41467-019-14177-z
Walsh, J. et al. Drug-gut microbiota interactions: Implications for neuropharmacology. Br. J. Pharmacol. 175(24), 4415–4429 (2018).
pubmed: 29782640
pmcid: 6255959
doi: 10.1111/bph.14366
Wilmanski, T. et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nat. Metab. 3(2), 274–286 (2021).
pubmed: 33619379
pmcid: 8169080
doi: 10.1038/s42255-021-00348-0
Wu, Y. L. et al. Gut microbiota alterations and health status in aging adults: From correlation to causation. Aging Med. (Milton). 4(3), 206–213 (2021).
pubmed: 34553118
doi: 10.1002/agm2.12167
Manor, O. et al. Health and disease markers correlate with gut microbiome composition across thousands of people. Nat. Commun. 11(1), 5206 (2020).
pubmed: 33060586
pmcid: 7562722
doi: 10.1038/s41467-020-18871-1
Procházková, N. et al. Advancing human gut microbiota research by considering gut transit time. Gut(2022).
Vandeputte, D. et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 65(1), 57–62 (2016).
pubmed: 26069274
doi: 10.1136/gutjnl-2015-309618
Tropini, C. How the physical environment shapes the microbiota. mSystems. 6(4), e0067521 (2021).
pubmed: 34427510
doi: 10.1128/msystems.00675-21
Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 352(6285), 565–569 (2016).
pubmed: 27126040
pmcid: 5240844
doi: 10.1126/science.aad3369
Hammer, J. & Phillips, S. F. Fluid loading of the human colon: Effects on segmental transit and stool composition. Gastroenterology. 105(4), 988–998 (1993).
pubmed: 8405884
doi: 10.1016/0016-5085(93)90941-5
Lewis, S. J. & Heaton, K. W. Stool form scale as a useful guide to intestinal transit time. Scand. J. Gastroenterol. 32(9), 920–924 (1997).
pubmed: 9299672
doi: 10.3109/00365529709011203
Blake, M. R., Raker, J. M. & Whelan, K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 44(7), 693–703 (2016).
pubmed: 27492648
doi: 10.1111/apt.13746
Nordin, E. et al. Modest conformity between self-reporting of Bristol Stool Form and fecal consistency measured by Stool Water Content in Irritable Bowel Syndrome and a FODMAP and Gluten Trial. Am. J. Gastroenterol. 117(10), 1668–1674 (2022).
pubmed: 36087104
doi: 10.14309/ajg.0000000000001942
Galazzo, G. et al. How to count our microbes? The effect of different quantitative microbiome profiling approaches. Front. Cell. Infect. Microbiol. 10, 403 (2020).
pubmed: 32850498
pmcid: 7426659
doi: 10.3389/fcimb.2020.00403
Knight, R. et al. Best practices for analysing microbiomes. Nat. Rev. Microbiol. 16(7), 410–422 (2018).
pubmed: 29795328
doi: 10.1038/s41579-018-0029-9
Vandeputte, D. et al. Quantitative microbiome profiling links gut community variation to microbial load. Nature. 551(7681), 507–511 (2017).
pubmed: 29143816
doi: 10.1038/nature24460
Gutierrez, M. W. & Arrieta, M. C. The intestinal mycobiome as a determinant of host immune and metabolic health. Curr. Opin. Microbiol. 62, 8–13 (2021).
pubmed: 33993019
doi: 10.1016/j.mib.2021.04.004
Shuai, M. et al. Mapping the human gut mycobiome in middle-aged and elderly adults: multiomics insights and implications for host metabolic health. Gut(2022).
Zhang, L. et al. The role of gut mycobiome in health and diseases. Ther. Adv. Gastroenterol. 14, 17562848211047130 (2021).
doi: 10.1177/17562848211047130
Chen, H. et al. A Forward Chemical genetic screen reveals gut microbiota metabolites that modulate host physiology. Cell. 177(5), 1217–1231e18 (2019).
pubmed: 31006530
pmcid: 6536006
doi: 10.1016/j.cell.2019.03.036
Krautkramer, K. A., Fan, J. & Bäckhed, F. Gut microbial metabolites as multi-kingdom intermediates. Nat. Rev. Microbiol. 19(2), 77–94 (2021).
pubmed: 32968241
doi: 10.1038/s41579-020-0438-4
Schroeder, B. O. & Bäckhed, F. Signals from the gut microbiota to distant organs in physiology and disease. Nat. Med. 22(10), 1079–1089 (2016).
pubmed: 27711063
doi: 10.1038/nm.4185
Visconti, A. et al. Interplay between the human gut microbiome and host metabolism. Nat. Commun. 10(1), 4505 (2019).
pubmed: 31582752
pmcid: 6776654
doi: 10.1038/s41467-019-12476-z
Zheng, X., Cai, X. & Hao, H. Emerging targetome and signalome landscape of gut microbial metabolites. Cell. Metab. 34(1), 35–58 (2022).
pubmed: 34986337
doi: 10.1016/j.cmet.2021.12.011
Blaak, E. et al. Short chain fatty acids in human gut and metabolic health. Benef. Microbes. 11(5), 411–455 (2020).
pubmed: 32865024
doi: 10.3920/BM2020.0057
Rios-Covian, D. et al. An overview on fecal branched short-chain fatty acids along human life and as related with body mass index: Associated dietary and anthropometric factors. Front. Microbiol. 11, 973 (2020).
pubmed: 32547507
pmcid: 7271748
doi: 10.3389/fmicb.2020.00973
Ramos Meyers, G., Samouda, H. & Bohn, T. Short chain fatty acid metabolism in relation to gut microbiota and genetic variability. Nutrients 14(24) (2022).
Yamamura, R. et al. Intestinal and fecal pH in human health. Front. Microbiomes 2(2023).
Firrman, J. et al. The impact of environmental pH on the gut microbiota community structure and short chain fatty acid production. FEMS Microbiol. Ecol. 98(5). (2022).
Procházková, N. et al. Gut environmental factors explain variations in the gut microbiome composition and metabolism within and between healthy adults. bioRxiv 2024.01.23.574598. (2024).
LaBouyer, M. et al. Higher total faecal short-chain fatty acid concentrations correlate with increasing proportions of butyrate and decreasing proportions of branched-chain fatty acids across multiple human studies. Gut Microbiome 3(2022).
Prata, M. M. G. et al. Comparisons between myeloperoxidase, lactoferrin, calprotectin and lipocalin-2, as fecal biomarkers of intestinal inflammation in malnourished children. J. Transl. Sci. 2(2), 134 (2016).
pubmed: 27746954
pmcid: 5061054
Gubatan, J. et al. Antimicrobial peptides and the gut microbiome in inflammatory bowel disease. World J. Gastroenterol. 27(43), 7402 (2021).
pubmed: 34887639
pmcid: 8613745
doi: 10.3748/wjg.v27.i43.7402
Padoan, A. et al. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability. Clin. Chem. Lab. Med. 56(11), 1926–1935 (2018).
pubmed: 29729144
doi: 10.1515/cclm-2018-0134
Hansberry, D. R. et al. Fecal myeloperoxidase as a biomarker for inflammatory bowel disease. Cureus. 9(1), e1004 (2017).
pubmed: 28286723
pmcid: 5332167
Johnson, A. J. et al. Daily sampling reveals personalized diet-microbiome associations in humans. Cell. Host Microbe. 25(6), 789–802e5 (2019).
pubmed: 31194939
doi: 10.1016/j.chom.2019.05.005
Vandeputte, D. et al. Temporal variability in quantitative human gut microbiome profiles and implications for clinical research. Nat. Commun. 12(1), 6740 (2021).
pubmed: 34795283
pmcid: 8602282
doi: 10.1038/s41467-021-27098-7
Vork, L. et al. Does day-to-day variability in Stool consistency link to the fecal microbiota composition? Front. Cell. Infect. Microbiol. 11, 639667 (2021).
pubmed: 34458156
pmcid: 8386168
doi: 10.3389/fcimb.2021.639667
David, L. A. et al. Host lifestyle affects human microbiota on daily timescales. Genome Biol. 15(7), R89 (2014).
pubmed: 25146375
pmcid: 4405912
doi: 10.1186/gb-2014-15-7-r89
Turroni, S. et al. Temporal dynamics of the gut microbiota in people sharing a confined environment, a 520-day ground-based space simulation, MARS500. Microbiome. 5(1), 39 (2017).
pubmed: 28340597
pmcid: 5366131
doi: 10.1186/s40168-017-0256-8
Venkataraman, A. et al. Variable responses of human microbiomes to dietary supplementation with resistant starch. Microbiome. 4(1), 33 (2016).
pubmed: 27357127
pmcid: 4928258
doi: 10.1186/s40168-016-0178-x
McOrist, A. L. et al. Bacterial population dynamics and faecal short-chain fatty acid (SCFA) concentrations in healthy humans. Br. J. Nutr. 100(1), 138–146 (2008).
pubmed: 18205991
doi: 10.1017/S0007114507886351
Karu, N. et al. A review on human fecal metabolomics: Methods, applications and the human fecal metabolome database. Anal. Chim. Acta. 1030, 1–24 (2018).
pubmed: 30032758
doi: 10.1016/j.aca.2018.05.031
Hosseinkhani, F. et al. Towards standards for human fecal sample preparation in targeted and untargeted LC-HRMS studies. Metabolites 11(6). (2021).
Johnson, A. J. et al. A guide to diet-microbiome study design. Front. Nutr. 7, 79 (2020).
pubmed: 32596250
pmcid: 7303276
doi: 10.3389/fnut.2020.00079
De Saedeleer, B. et al. Systematic characterization of human gut microbiome-secreted molecules by integrated multi-omics. ISME Commun. 1, 82 (2021).
pubmed: 35106519
pmcid: 7612290
doi: 10.1038/s43705-021-00078-0
Deda, O. et al. Sample preparation optimization in fecal metabolic profiling. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1047, 115–123 (2017).
doi: 10.1016/j.jchromb.2016.06.047
Hassani, E. M. E. Optimized sample preparation for fecal volatile organic compound analysis by gas chromatography-mass spectrometry. Metabolomics. 16(10), 112 (2020).
doi: 10.1007/s11306-020-01735-6
Gratton, J. et al. Optimized sample handling strategy for metabolic profiling of human feces. Anal. Chem. 88(9), 4661–4668 (2016).
pubmed: 27065191
doi: 10.1021/acs.analchem.5b04159
Lamichhane, S. et al. Gut metabolome meets microbiome: A methodological perspective to understand the relationship between host and microbe. Methods. 149, 3–12 (2018).
pubmed: 29715508
doi: 10.1016/j.ymeth.2018.04.029
Liang, Y. et al. Systematic analysis of impact of sampling regions and Storage methods on fecal gut microbiome and metabolome profiles. mSphere 5(1). (2020).
Trošt, K. et al. Describing the fecal metabolome in cryogenically collected samples from healthy participants. Sci. Rep. 10(1), 885 (2020).
pubmed: 31965056
pmcid: 6972823
doi: 10.1038/s41598-020-57888-w
Hsieh, Y. H. et al. Impact of different fecal Processing methods on assessments of bacterial diversity in the human intestine. Front. Microbiol. 7, 1643 (2016).
pubmed: 27812352
pmcid: 5071325
doi: 10.3389/fmicb.2016.01643
Jones, J. et al. Fecal sample collection methods and time of day impact microbiome composition and short chain fatty acid concentrations. Sci. Rep. 11(1), 13964 (2021).
pubmed: 34234185
pmcid: 8263620
doi: 10.1038/s41598-021-93031-z
Wu, W. K. et al. Optimization of fecal sample processing for microbiome study - The journey from bathroom to bench. J. Formos. Med. Assoc. 118(2), 545–555 (2019).
pubmed: 29490879
doi: 10.1016/j.jfma.2018.02.005
Bruce, K. et al. A Practical Guide to DNA-based Methods for Biodiversity Assessment(Pensoft Advanced Books, 2021).
Gorzelak, M. A. et al. Methods for improving human gut microbiome data by reducing variability through sample processing and storage of stool. PLOS ONE. 10(8), e0134802 (2015).
pubmed: 26252519
pmcid: 4529225
doi: 10.1371/journal.pone.0134802
Chumpitazi, B. P. et al. Bristol Stool Form Scale reliability and agreement decreases when determining Rome III stool form designations. Neurogastroenterol.Motil. 28(3), 443–448 (2016).
pubmed: 26690980
doi: 10.1111/nmo.12738
Siigur, U. et al. Concentrations and correlations of faecal short-chain fatty acids and faecal water content in man. Microb. Ecol. Health Dis. 7(6), 287–294 (1994).
Hallen-Adams, H. E. Fungi inhabiting the healthy human gastrointestinal tract: A diverse and dynamic community. Fungal Ecol. 15, 9–17 (2015).
doi: 10.1016/j.funeco.2015.01.006
Hallen-Adams, H. E. & Suhr, M. J. Fungi in the healthy human gastrointestinal tract. Virulence. 8(3), 352–358 (2017).
pubmed: 27736307
doi: 10.1080/21505594.2016.1247140
Raimondi, S. et al. Longitudinal survey of Fungi in the human gut: ITS profiling, phenotyping, and colonization. Front. Microbiol. 10, 1575 (2019).
pubmed: 31354669
pmcid: 6636193
doi: 10.3389/fmicb.2019.01575
Auchtung, T. A. et al. Investigating colonization of the healthy adult gastrointestinal tract by fungi. mSphere. 3(2) (2018).
Underhill, D. M. & Iliev, I. D. The mycobiota: Interactions between commensal fungi and the host immune system. Nat. Rev. Immunol. 14(6), 405–416 (2014).
pubmed: 24854590
pmcid: 4332855
doi: 10.1038/nri3684
David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 505(7484), 559–563 (2014).
pubmed: 24336217
doi: 10.1038/nature12820
Stephen, A. M., Wiggins, H. S. & Cummings, J. H. Effect of changing transit time on colonic microbial metabolism in man. Gut. 28(5), 601–609 (1987).
pubmed: 3596341
pmcid: 1432874
doi: 10.1136/gut.28.5.601
Daniel, H. Diet and gut microbiome and the chicken or egg problem. Front. Nutr. 8(2022).
Tibble, J. et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 47(4), 506–513 (2000).
pubmed: 10986210
pmcid: 1728060
doi: 10.1136/gut.47.4.506
Kristensen, V. et al. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: Intra-individual variability and standardisation of sampling procedure. Scand. J. Gastroenterol. 51(5), 548–555 (2016).
pubmed: 26634305
doi: 10.3109/00365521.2015.1117650
Cremer, A. et al. Variability of faecal calprotectin in inflammatory bowel disease patients: An observational case-control study. J. Crohn’s Colitis. 13(11), 1372–1379 (2019).
doi: 10.1093/ecco-jcc/jjz069
Lasson, A. et al. The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis. J. Crohn’s Colitis. 9(1), 26–32 (2014).
D’Amico, F. et al. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United Eur. Gastroenterol. J. 9(4), 451–460 (2021).
doi: 10.1002/ueg2.12069
Swaminathan, A. et al. Faecal myeloperoxidase as a biomarker of endoscopic activity in inflammatory bowel disease. J. Crohn’s Colitis. 16(12), 1862–1873 (2022).
doi: 10.1093/ecco-jcc/jjac098
Olsson, L. M. et al. Dynamics of the normal gut microbiota: A longitudinal one-year population study in Sweden. Cell. Host Microbe. 30(5), 726–739e3 (2022).
pubmed: 35349787
doi: 10.1016/j.chom.2022.03.002
Zhou, X. et al. Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease. Cell. Host Microbe. 32(4), 506–526e9 (2024).
pubmed: 38479397
doi: 10.1016/j.chom.2024.02.012
Gupta, R. S. & Gao, B. Phylogenomic analyses of clostridia and identification of novel protein signatures that are specific to the genus Clostridiumsensu stricto (cluster I). Int. J. Syst. Evol. MicroBiol. 59(2), 285–294 (2009).
pubmed: 19196767
doi: 10.1099/ijs.0.001792-0
Li, C. J. et al. Comparative genomic analysis and proposal of Clostridium yunnanense sp. nov., Clostridium rhizosphaerae sp. nov., and Clostridium paridis sp. nov., three novel Clostridium sensu stricto endophytes with diverse capabilities of acetic acid and ethanol production. Anaerobe. 79, 102686 (2023).
pubmed: 36535584
doi: 10.1016/j.anaerobe.2022.102686
Wiegel, J., Tanner, R. & Rainey, F. A. The Prokaryotes Volume 4. Bacteria: Firmicutes, Cyanobacteria. An Introduction to the Family Clostridiaceae.(ed. Dworkin, M.). Vol. 4. (Springer)
Liu, L. et al. Clostridium butyricum potentially improves immunity and nutrition through alteration of the microbiota and metabolism of elderly people with malnutrition in long-term care. Nutrients 14(17). (2022).
Sun, Y. Y. et al. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. Sci. Rep. 8(1), 2964 (2018).
pubmed: 29445178
pmcid: 5813237
doi: 10.1038/s41598-018-21241-z
Geerlings, S. Y. et al. Akkermansia muciniphila in the human gastrointestinal tract: When, where, and how? Microorganisms 6(3). (2018).
Zhang, T. et al. Akkermansia muciniphila is a promising probiotic. Microb. Biotechnol. 12(6), 1109–1125 (2019).
pubmed: 31006995
pmcid: 6801136
doi: 10.1111/1751-7915.13410
Ezzy, A. C. et al. Storage and handling of human faecal samples affect the gut microbiome composition: a feasibility study. J. Microbiol. Methods. 164, 105668 (2019).
pubmed: 31302202
doi: 10.1016/j.mimet.2019.105668
Gangadoo, S. et al. The multiomics analyses of fecal matrix and its significance to coeliac disease gut profiling. Int. J. Mol. Sci. 22(4) (2021).
Ostapowicz, J. et al. Comparison of Tumour Tissue Homogenisation Methods: Mortar and Pestle Versus Ball Mill.(2023).
Siddiqui, I., Majid, H. & Abid, S. Update on clinical and research application of fecal biomarkers for gastrointestinal diseases. World J. Gastrointest. Pharmacol. Ther. 8(1), 39–46 (2017).
pubmed: 28217373
pmcid: 5292605
doi: 10.4292/wjgpt.v8.i1.39
Ueyama, J. et al. Freeze-drying enables homogeneous and stable sample preparation for determination of fecal short-chain fatty acids. Anal. Biochem. 589, 113508 (2020).
pubmed: 31751532
doi: 10.1016/j.ab.2019.113508
McOrist, A. L. et al. Fecal butyrate levels vary widely among individuals but are usually increased by a diet high in resistant starch. J. Nutr. 141(5), 883–889 (2011).
pubmed: 21430242
doi: 10.3945/jn.110.128504
Roager, H. M. & Dragsted, L. O. Diet-derived microbial metabolites in health and disease. Nutr. Bull. 44(3), 216–227 (2019).
doi: 10.1111/nbu.12396
Asnicar, F. et al. Blue poo: Impact of gut transit time on the gut microbiome using a novel marker. Gut. 70(9), 1665–1674 (2021).
pubmed: 33722860
doi: 10.1136/gutjnl-2020-323877
Million, M. et al. Increased gut Redox and depletion of anaerobic and methanogenic prokaryotes in severe acute malnutrition. Sci. Rep. 6, 26051 (2016).
pubmed: 27183876
pmcid: 4869025
doi: 10.1038/srep26051
Lotti, C. et al. Development of a fast and cost-effective gas chromatography–mass spectrometry method for the quantification of short-chain and medium-chain fatty acids in human biofluids. Anal. Bioanal. Chem. 409(23), 5555–5567 (2017).
pubmed: 28717897
doi: 10.1007/s00216-017-0493-5
Tsugawa, H. et al. A lipidome atlas in MS-DIAL 4. Nat. Biotechnol. 38(10), 1159–1163 (2020).
pubmed: 32541957
doi: 10.1038/s41587-020-0531-2
Schmid, R. et al. Integrative analysis of multimodal mass spectrometry data in MZmine 3. Nat. Biotechnol. 41(4), 447–449 (2023).
pubmed: 36859716
pmcid: 10496610
doi: 10.1038/s41587-023-01690-2
Liu, C. M. et al. BactQuant: an enhanced broad-coverage bacterial quantitative real-time PCR assay. BMC Microbiol. 12(1), 56 (2012).
pubmed: 22510143
pmcid: 3464140
doi: 10.1186/1471-2180-12-56
Liu, C. M. et al. FungiQuant: a broad-coverage fungal quantitative real-time PCR assay. BMC Microbiol. 12(1), 255 (2012).
pubmed: 23136846
pmcid: 3565980
doi: 10.1186/1471-2180-12-255
Rios-Morales, M. et al. A toolbox for the comprehensive analysis of small volume human intestinal samples that can be used with gastrointestinal sampling capsules. Sci. Rep. 11(1), 1–14 (2021).
doi: 10.1038/s41598-021-86980-y
Poncheewin, W. et al. NG-Tax 2.0: a semantic framework for high-throughput amplicon analysis. Front. Genet. 10, 1366 (2020).
pubmed: 32117417
pmcid: 6989550
doi: 10.3389/fgene.2019.01366
Langille, M. G. et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat. Biotechnol. 31(9), 814–821 (2013).
pubmed: 23975157
pmcid: 3819121
doi: 10.1038/nbt.2676
Caspi, R. et al. The MetaCyc database of metabolic pathways and enzymes. Nucleic Acids Res. 46(D1), D633–D639 (2017).
pmcid: 5753197
doi: 10.1093/nar/gkx935
Koo, T. K. & Li, M. Y. A Guideline of selecting and reporting Intraclass correlation coefficients for Reliability Research. J. Chiropr. Med. 15(2), 155–163 (2016).
pubmed: 27330520
pmcid: 4913118
doi: 10.1016/j.jcm.2016.02.012